Accueil   Diary - News   All news First Patient Randomized in Multiple Dose Cohort Of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients

First Patient Randomized in Multiple Dose Cohort Of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients

TRANSGENE NEWSLETTER
 

Transgene (Euronext Paris: TNG), a company  focused on designing and developing targeted  immunotherapies for the treatment of cancer and  infectious diseases, today announced  that the first patient  has been included in the  multiple dose  cohort of the Phase1/1b trial with TG1050, Transgene’s immunotherapy product candidate for the  treatment of chronic hepatitis B virus (HBV) infection (NCT: 02428400).

 
 
 
Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree